Artificial intelligence for diabetic retinopathy in low-income and middle-income countries: a scoping review
Authors' conclusion
The reported sensitivities and specificities were generally high providing evidence to support use in clinical practice. However, the majority of studies focused on sensitivity and specificity only and there was limited information on cost, regulatory approvals and whether the use of AI improved health outcomes.
Study context
- Population
- Artificial intelligence (AI) tools used for diabetic retinopathy (DR) in LMICs81 articles
- Outcome
- Performance of AI tools for DR in LMICs
Main finding
As reported in the abstract
- Reported sensitivities and specificities were generally high
- Most studies focused on sensitivity and specificity only; limited information on cost, regulatory approvals and whether AI improved health outcomes
Original publication
Artificial intelligence for diabetic retinopathy in low-income and middle-income countries: a scoping review. BMJ Open Diabetes Res Care. Published 2 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →